Clin2
NCT03952065Possibly a fitRecruiting

Neck artery immune-therapy vs IV for head and neck cancer

Head/Neck Neoplasm

Part of Cancer clinical trials.

This trial compares giving immune therapy into the neck artery versus giving it through a vein (IV) for people with head and neck cancers. It aims to see which method works better and is safer by helping the immune system attack the cancer.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2/Phase 3
Enrollment
200 people
Ages
18 years to 80 years
Study type
Interventional

Who can take part

  • Have head and neck cancer confirmed by tissue biopsy (microscope test)
  • Be 18 to 80 years old, and your doctors expect you to live more than 3 months
  • Be well enough for study treatment (ECOG score less than 2)
  • Have “measurable” tumors on scans that can be tracked over time
  • Recent blood tests must meet targets (white blood cells, hemoglobin, platelets, liver function, kidney function, and clotting)

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07090707Not yet recruiting· Phase 2
Comparing immunotherapy to radiation after chemo-immunotherapy for head and neck cancer

This trial is for people with advanced head and neck cancer who had good response to chemotherapy plus immunotherapy before surgery. It compares two different follow-up treatments: more immunotherapy or radiation therapy to help prevent cancer from coming back.

Guangzhou, Guangdong
NCT05980715Recruiting· Phase 3
Comparing immunotherapy to radiation after successful treatment for head and neck cancer

This trial looks at whether giving an immunotherapy drug (a PD-1 inhibitor) after surgery is better than giving radiation therapy for people with advanced head and neck cancer who had a complete response to chemotherapy and immunotherapy before surgery. The goal is to prevent the cancer from coming back.

Guangzhou, Guangdong
NCT05343325Recruiting· Phase 2
Neoadjuvant low-dose radiation with chemo-immunotherapy for head and neck cancer

This Phase 2 study tests whether giving low-dose radiation before surgery—along with chemotherapy and an immunotherapy drug—can work better and be safe for treating locally advanced head and neck squamous cell cancer. It may help shrink tumors before surgery and reduce the chance of the cancer coming back.

Zhuhai, Guangdong
NCT06016413Not yet recruiting· Phase 2
Immunotherapy and Chemotherapy Before Surgery for Head and Neck Cancer

This trial tests a new combination of an immunotherapy drug (adelbelimab) plus chemotherapy given before surgery for head and neck cancer. The goal is to see if this treatment can shrink tumors and improve outcomes for people with advanced but removable head and neck squamous cell carcinoma.

Guangzhou, Guangdong
NCT06725498Recruiting· Phase 2
Chemo, radiation, and immunotherapy for advanced head and neck cancer

This trial tests a combination of chemotherapy directly into an artery, radiation, and immunotherapy for advanced head and neck cancer. It may offer a new treatment option for people whose cancer hasn't spread to other parts of the body.

Beijing, Beijing Municipality
NCT06345287Recruiting· Phase 2
Adaptive radiotherapy after immunotherapy for head and neck cancer

This trial tests a personalized radiotherapy approach after a few rounds of chemo-immunotherapy for people with HPV-negative head and neck cancer. It aims to adjust the radiation dose based on how the tumor responds, possibly reducing side effects while still controlling the cancer.

Beijing

Hear when a new Head/Neck Neoplasm trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.